Status:
COMPLETED
Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Candidiasis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Candida is the most common fungal pathogen identified in hospitalized patients. This study will seek to enroll adult patients (18 years of age or older) with invasive Candida infections (involving dee...
Eligibility Criteria
Inclusion
- All patients must have at least 1 positive culture for Candida species obtained from an otherwise sterile, non-blood body site within 96 hours of the study entry.
- The patient must also have clinical evidence of Candida infection (e.g., oral temperature \>100 degrees Fahrenheit, signs of inflammation from infected site, systolic blood pressure \<90) within 96 hours of study entry.
- The patient must be at least 18 years old, and if a woman of child bearing potential, must have a negative serum or urine pregnancy test sensitive to 25 IU HCG prior to enrollment.
Exclusion
- Patients whose only site of Candida infection was the bloodstream.
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2006
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00083343
Start Date
May 1 2004
End Date
February 1 2006
Last Update
February 23 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.